Reaction
Nail Bed Inflammation reporting signals
As of the last recalculation, Nail Bed Inflammation appears in 314 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 339.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 38 | 339.8 | 341.3 |
| Carboxymethylcellulose Sodium | 37 | 295.7 | 296.9 |
| Dronabinol | 29 | 263.3 | 264.2 |
| Bleomycin Sulfate | 35 | 252.6 | 253.5 |
| Lapatinib | 38 | 184.6 | 185.0 |
| Fam-Trastuzumab Deruxtecan-Nxki | 25 | 178.5 | 179.0 |
| Fosaprepitant Dimeglumine | 28 | 148.1 | 148.4 |
| Pertuzumab | 46 | 131.2 | 131.5 |
| Aprepitant | 29 | 114.6 | 114.8 |
| Trazodone Hydrochloride | 23 | 105.1 | 105.3 |
| Panitumumab | 21 | 95.2 | 95.3 |
| Fulvestrant | 39 | 89.2 | 89.3 |
| Doxorubicin Hydrochloride | 34 | 77.3 | 77.4 |
| Lactulose | 37 | 72.4 | 72.5 |
| Cefepime Hydrochloride | 15 | 64.8 | 64.8 |
| Cefepime | 12 | 57.7 | 57.7 |
| Trastuzumab | 47 | 53.2 | 53.2 |
| Amphotericin B | 9 | 49.0 | 49.0 |
| Cetuximab | 21 | 47.5 | 47.6 |
| Capecitabine | 53 | 46.0 | 46.0 |
| Granisetron Hydrochloride | 7 | 45.4 | 45.4 |
| Filgrastim | 22 | 41.6 | 41.6 |
| Granisetron | 6 | 38.6 | 38.7 |
| Docetaxel Anhydrous | 30 | 32.5 | 32.5 |
| Docetaxel | 30 | 32.5 | 32.5 |
| Ocrelizumab | 22 | 25.2 | 25.2 |
| Pegfilgrastim | 23 | 16.6 | 16.6 |